Max Healthcare Share Price Jumps 6% to Lead Nifty 50 on 18 June 2026; Citi Sees 20% EBITDA CAGR to FY30

Max Healthcare share price surged up to 6% on 18 June 2026, touching a day high of Rs 1,088 and emerging as the top Nifty 50 gainer, after Citi reiterated a Buy rating with a Rs 1,240 target citing an attractive entry point after the stock’s 18% correction and projecting a 20% EBITDA compound annual growth rate from FY26 to FY30. The brokerage highlighted new hospital capacity additions, recovery in the oncology segment and an improving payer mix as the three key drivers behind the EBITDA re-rating thesis, which pushed Max Healthcare share price to its session high before a partial pullback to Rs 1,077.75.

Click Here – Get Free Investment Predictions

Max Healthcare Key Data at a Glance

Max Healthcare Data	Detail (18 June 2026)
Max Healthcare (NSE: MAXHEALTH)	Rs 1,077.75 (+5%) | Day High Rs 1,088 (+6%)
Previous Close	Rs 1,026.15
52-Week High / Low	Rs 1,314.30 / Rs 903.00
Market Cap	~Rs 99,869 crore (~Rs 1 lakh crore)
Citi Rating	Buy | Target Rs 1,240 | ~15% upside
Citi EBITDA CAGR Forecast	20% CAGR FY26-30E
Key EBITDA Drivers	New capacity + oncology recovery + better payer mix
FY26 Revenue	Rs 8,373 crore (+19% YoY)
FY26 Net Profit	Rs 1,442 crore (+34% YoY)
Q4 FY26 Network EBITDA Margin	26.8%
Network Size	21 hospitals | ~6,000 beds

Citi’s 20% EBITDA CAGR Thesis: Why Max Healthcare Is a Nifty Gainer Today

Max Healthcare share price is the top Nifty gainer on 18 June because Citi’s thesis combines two powerful ingredients: a clear earnings growth roadmap and a recently corrected stock price. The 18% decline from the highs had created an entry opportunity for investors who missed the earlier rally. Citi’s 20% EBITDA CAGR from FY26 to FY30 is grounded in three concurrent growth drivers, each of which operates independently, meaning if even two of the three execute well, the EBITDA target is achievable. FY26 already delivered a 34% net profit increase, providing a solid base.

Use the Univest Screener to compare Max Healthcare with Fortis, Narayana Hrudayalaya and Apollo

What Drives Max Healthcare’s 20% EBITDA CAGR to FY30

Driver	What It Means for Max Healthcare EBITDA
New Hospital Capacity	More beds = higher volume; new units ramp to full occupancy over 2-3 years
Oncology Recovery	High-margin oncology disrupted short-term; normalisation lifts EBITDA per patient
Better Payer Mix	International patients (~9% of hospital revenue) and corporate insurance pay more

1. New Capacity: The Expansion Pipeline

Max Healthcare has been actively investing in expanding its hospital network. The Rs 328 crore deployed in Q4 FY26 alone for expansion and new unit upgrades signals an ongoing capex cycle. As new capacity beds fill up over 18-24 months, revenue and EBITDA per hospital improve significantly because fixed costs are already incurred. The recently acquired Kalinga Hospital in Bhubaneswar adds 250 beds and a new geography. This expansion pipeline is the most visible driver of the 20% EBITDA CAGR.

2. Oncology Recovery

Oncology is one of the highest-margin segments in Indian hospital chains. Short-term disruptions from changes in clinical staff and treatment protocols had weighed on the segment’s contribution. Citi expects a normalisation and growth acceleration in oncology as India’s cancer burden grows and awareness rises. Max Healthcare’s centres of excellence in oncology give it a premium positioning to capture this high-ARPU segment.

3. Improving Payer Mix

International patient revenue was Rs 227 crore in Q4 FY26, up 12% year-on-year, contributing approximately 9% of hospital revenue. International patients typically have significantly higher average revenue per occupied bed than domestic patients, and corporate insurance contracts generate better realisations than cash or public insurance payers. As both segments grow, the overall payer mix improves, directly expanding EBITDA margins without requiring additional beds.

Download the Univest iOS App or Univest Android App to track Max Healthcare share price live and get healthcare sector expert recommendations.

Conclusion

Max Healthcare share price surged up to 6% to a day high of Rs 1,088 on 18 June 2026, making it the top Nifty 50 gainer, after Citi reiterated its Buy rating with a Rs 1,240 target and projected a 20% EBITDA CAGR from FY26 to FY30 driven by new capacity, oncology recovery and improving payer mix. With FY26 PAT up 34% and market cap near Rs 1 lakh crore, the growth trajectory is strong, but the stock trades at a premium valuation of approximately 69x PE. Consult a SEBI-registered financial advisor before investing.

Why is Max Healthcare share price rising 6% today?

Ans. Max Healthcare share price surged up to 6% to a day high of Rs 1,088 on 18 June 2026 after Citi reiterated a Buy rating with a target price of Rs 1,240, citing an attractive entry post a roughly 18% correction in the stock. Citi projected a 20% EBITDA compound annual growth rate from FY26 to FY30, driven by new hospital capacity coming online, a recovery in the oncology segment and an improving payer mix. The combination of strong institutional conviction and compelling growth visibility made Max Healthcare the top Nifty 50 gainer on June 18.

What is Citi’s rating and target for Max Healthcare?

Ans. Citi maintains a Buy rating on Max Healthcare with a target price of Rs 1,240, implying approximately 15% upside from the June 18 CMP of Rs 1,077.75. The brokerage identified the stock as an attractive entry after an 18% correction from its highs. Citi’s thesis rests on a 20% EBITDA CAGR from FY26 to FY30, supported by: new hospital capacity additions, recovery in the oncology segment which had been under pressure, and an improving payer mix toward higher-revenue international and corporate patients.

What is the 20% EBITDA CAGR thesis for Max Healthcare?

Ans. Citi’s 20% EBITDA CAGR for Max Healthcare from FY26 to FY30 rests on three drivers. First, new capacity additions: Max Healthcare is investing in expanding its hospital network and adding beds at existing facilities, which supports volume-led revenue growth as capacity ramps up. Second, oncology recovery: the oncology segment faced short-term disruptions but is expected to normalise and grow rapidly given India’s rising cancer incidence. Third, improving payer mix: a shift toward higher-revenue international patients and better corporate insurance contracts improves revenue per occupied bed and EBITDA margins.

What is Max Healthcare share price today on 18 June 2026?

Ans. Max Healthcare share price (NSE: MAXHEALTH) is Rs 1,077.75 as of 18 June 2026, gaining approximately 5% from the previous close of Rs 1,026.15. The stock touched a day high of Rs 1,088, up approximately 6%, to become the top Nifty 50 gainer. The 52-week high is Rs 1,314.30 and the 52-week low is Rs 903. At the current price of Rs 1,077.75, Max Healthcare is approximately 18% below its 52-week high and approximately 19% above its 52-week low.

What are Max Healthcare’s key financial results?

Ans. Max Healthcare reported FY26 consolidated revenue of Rs 8,373 crore, up 19% year-on-year, and net profit of Rs 1,442 crore, up 34%. For Q4 FY26, revenue was Rs 2,143 crore (+12% YoY), network EBITDA was Rs 682 crore (+8% YoY) at a margin of 26.8%, and network PAT was Rs 387 crore. The company has expanded to 21 hospitals with approximately 6,000 beds, with significant presence in North India, and is in the early stages of integrating Kalinga Hospital in Bhubaneswar after acquiring a 58.39% stake.

How many hospitals does Max Healthcare operate?

Ans. Max Healthcare operates 21 healthcare facilities with approximately 6,000 beds across India as of June 2026. Its network is concentrated in North India, with flagship hospitals in Delhi NCR. Beyond hospitals, the company operates Max@Home (homecare services, Rs 73 crore revenue in Q4, +30% YoY) and Max Lab (non-captive pathology, Rs 52 crore in Q4, across 60+ cities). The company recently acquired a controlling 58.39% stake in Kalinga Hospital in Bhubaneswar, expanding its footprint in eastern India.

What is the 52-week range for Max Healthcare share price?

Ans. Max Healthcare share price has a 52-week high of Rs 1,314.30 and a 52-week low of Rs 903 as of June 18, 2026. At the current price of Rs 1,077.75, the stock is approximately 18% below the 52-week high and approximately 19% above the 52-week low. Market cap is approximately Rs 99,869 crore. The stock has seen pressure over the past year from sector-wide valuation correction, making Citi’s call of an attractive entry after an 18% correction consistent with the technical setup.

Should investors buy Max Healthcare on today’s Citi note?

Ans. Citi’s Buy rating at Rs 1,240 implies approximately 15% upside from Rs 1,077.75. The 20% EBITDA CAGR thesis is backed by new capacity, oncology recovery and improving payer mix, and the stock has corrected roughly 18% from its highs. However, at a PE of approximately 69x and PB of approximately 9x, Max Healthcare trades at a premium valuation that assumes sustained high growth. Risks include clinician cost pressure, delayed capacity ramp, and competitive intensity. Consult a SEBI-registered financial advisor before investing.